Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review

Jeffrey B. Driban
Tufts Medical Center

Et al.

Let us know how access to this document benefits you.
Follow this and additional works at: https://escholarship.umassmed.edu/oapubs

Part of the Musculoskeletal Diseases Commons, Orthopedics Commons, Radiology Commons, and the Rheumatology Commons

Repository Citation
Driban JB, Harkey MS, Barbe MF, Ward RJ, MacKay JW, Davis JE, Lu B, Price LL, Eaton CB, Lo GH, McAlindon TE. (2020). Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review. Open Access Publications by UMass Chan Authors. https://doi.org/10.1186/s12891-020-03367-2. Retrieved from https://escholarship.umassmed.edu/oapubs/4235

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License. This material is brought to you by eScholarship@UMassChan. It has been accepted for inclusion in Open Access Publications by UMass Chan Authors by an authorized administrator of eScholarship@UMassChan. For more information, please contact Lisa.Palmer@umassmed.edu.
Risk factors and the natural history of accelerated knee osteoarthritis: a narrative review

Jeffrey B. Driban1*, Matthew S. Harkey1,2, Mary F. Barbe3, Robert J. Ward4, James W. MacKay5,6, Julie E. Davis7, Bing Lu8, Lori Lyn Price9,10, Charles B. Eaton11, Grace H. Lo12,13 and Timothy E. McAlindon1

Abstract

Background: Osteoarthritis is generally a slowly progressive disorder. However, at least 1 in 7 people with incident knee osteoarthritis develop an abrupt progression to advanced-stage radiographic disease, many within 12 months. We summarize what is known – primarily based on findings from the Osteoarthritis Initiative – about the risk factors and natural history of accelerated knee osteoarthritis (AKOA) – defined as a transition from no radiographic knee osteoarthritis to advanced-stage disease ≤ 4 years – and put these findings in context with typical osteoarthritis (slowly progressing disease), aging, prior case reports/series, and relevant animal models.

Summary: Risk factors in the 2 to 4 years before radiographic manifestation of AKOA (onset) include older age, higher body mass index, altered joint alignment, contralateral osteoarthritis, greater pre-radiographic disease burden (structural, symptoms, and function), or low fasting glucose. One to 2 years before AKOA onset people often exhibit rapid articular cartilage loss, larger bone marrow lesions and effusion-synovitis, more meniscal pathology, slower chair-stand or walking pace, and increased global impact of arthritis than adults with typical knee osteoarthritis. Increased joint symptoms predispose a person to new joint trauma, which for someone who develops AKOA is often characterized by a destabilizing meniscal tear (e.g., radial or root tear). One in 7 people with AKOA onset subsequently receive a knee replacement during a 9-year period. The median time from any increase in radiographic severity to knee replacement is only 2.3 years. Despite some similarities, AKOA is different than other rapidly progressive arthropathies and collapsing these phenomena together or extracting results from one type of osteoarthritis to another should be avoided until further research comparing these types of osteoarthritis is conducted. Animal models that induce meniscal damage in the presence of other risk factors or create an incongruent distribution of loading on joints create an accelerated form of osteoarthritis compared to other models and may offer insights into AKOA.

Conclusion: Accelerated knee osteoarthritis is unique from typical knee osteoarthritis. The incidence of AKOA in the Osteoarthritis Initiative and Chingford Study is substantial. AKOA needs to be taken into account and studied in epidemiologic studies and clinical trials.

Keywords: Knee, Osteoarthritis, Phenotype, Risk factors, Natural history, Magnetic resonance imaging, Radiography, Meniscus

* Correspondence: jeffrey.driban@tufts.edu
1Division of Rheumatology, Allergy & Immunology, Tufts Medical Center, 800 Washington Street, Box #406, Boston, MA 02111, USA
Full list of author information is available at the end of the article

© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Knee osteoarthritis is typically a slowly progressive disorder. However, approximately 3.4% of adults develop radiographic evidence of accelerated knee osteoarthritis (AKOA) over 4 years [1, 2]. Therefore, at least 1 in 7 cases of incident knee osteoarthritis develop AKOA [1, 2]. We define AKOA as a process characterized by the rapid onset and progression from pre-radiographic disease to advanced-stage radiographic disease in less than 4 years (Kellgren-Lawrence [KL] grades = 0 or 1 to KL = 3 or 4) [1, 3, 4]. For the purpose of this review we will define the “onset” of AKOA as the first visit with radiographic evidence of advanced-stage radiographic disease. Individuals that develop AKOA typically progress from no or doubtful knee osteoarthritis (KL 0 to 1) to definite joint space narrowing and osteophyte (KL = 3) [5]. Two out of 3 adults that develop AKOA will experience this sudden onset and progression (KL 0 or 1 to KL 3 or 4) within 1 year [1, 3–5].

Adults with AKOA represent an important proportion of adults with incident knee osteoarthritis. For example, at least 3 years before radiographic onset adults with incident AKOA have greater pain and disability compared to adults with a typical, gradual onset of knee osteoarthritis (KL 0 to 1) to definite joint space narrowing and osteophyte (KL = 3) [5]. Two out of 3 adults that develop AKOA will experience this sudden onset and progression (KL 0 or 1 to KL 3 or 4) within 1 year [1, 3–5].

To achieve our goal, we will start by reviewing the natural history of AKOA and its risk factors. The natural history will be divided into 3 phases: 1) 2 or more years before radiographic osteoarthritis onset, 2) 1 to 2 years before radiographic osteoarthritis onset, and 3) less than 1 year before radiographic onset. Within each phase, we will describe the clinical and structural changes that characterize each phase in comparison to adults with typical knee osteoarthritis or no knee osteoarthritis (representative of age-related changes). After summarizing the natural history of AKOA, we will describe the clinical consequences of AKOA, strategies to classify adults at risk for AKOA, and put AKOA into context with rapidly progressive osteoarthritis and destructive arthropathies.

Natural history of accelerated knee osteoarthritis and its risk factors
Numerous factors may contribute to AKOA and help people identify who will develop it. Similar to typical knee osteoarthritis, older age and body mass index (BMI) are related to AKOA onset [1, 9, 10]. However, two subgroups are at greater risk for AKOA: 1) individuals < 65 years of age with BMI > 32.5 kg/m² and 2) individuals > 65 years of age that were typically overweight or obese with BMI < 35 kg/m² (only 27% had BMI < 25 kg/m²) [10–12]. Greater age and BMI may contribute to the onset of AKOA through pathways related to hyperglycemia and elevated inflammation. However, contrary to this hypothesis, glycated serum protein concentrations, a biomarker of glucose homeostasis, associated with the subsequent onset of typical knee osteoarthritis but not AKOA [13]. There are also no statistical associations between serum concentrations of C-reactive protein or glucose and AKOA onset over the subsequent 4 years to those measurements [13]. It remains unknown if a change in biomarkers of systemic inflammation or glucose homeostasis occurs as people develop pre-radiographic structural changes that antedate radiographic disease onset.

Certain biomechanical factors may also contribute to AKOA. While the presence of static knee malalignment does not significantly differ between individuals who will develop AKOA or typical knee osteoarthritis, greater coronal tibial slope (describing the slope of the tibial plateau relative to a perpendicular line to the long axis of the tibia) is related with a greater odds of incident AKOA but not typical knee osteoarthritis when
compared to adults without knee osteoarthritis. However, this relationship was only present among people who had a varus or valgus static malalignment [14]. Hence, a joint may tolerate aberrant coronal tibial slopes in isolation but become susceptible to failure when stressed by combining altered coronal tibial slope with static malalignment (i.e., varus or valgus malalignment).

2 or more years before radiographic osteoarthritis onset

**Clinical**

Individuals destined to develop AKOA are more likely to report more knee pain and knee-specific disability, as well as walk slower than adults who will develop typical knee osteoarthritis up to 3 years in advance of disease onset [5].

**Structural alterations**

Magnetic resonance images may reveal why people 2 years in advance of radiographic disease onset are more likely to report greater pain and dysfunction than individuals who develop typical knee osteoarthritis. For example, adults with infrapatellar fat pad signal-intensity alteration or large effusion-synovitis volume, assessed with magnetic resonance imaging, have roughly twice the odds of developing AKOA onset over the subsequent four years [15]. At least 2 years before radiographic onset, people who develop AKOA have greater effusion-synovitis volume compared with those who developed typical knee osteoarthritis [16]. Furthermore, adults who develop AKOA are more likely to have infrapatellar fat pad signal-intensity alteration than those with no knee osteoarthritis [16]. Effusion-synovitis volume and infrapatellar fat pad signal-intensity alteration may be reflective of local inflammation [17] and at least moderately related to knee pain [18–22].

Effusion-synovitis can be both a result of other joint damage or significant stress to a joint [22] or contribute to further aberrant structural changes [23]. Therefore, effusion-synovitis may be a key contributor that perpetuates a vicious cycle defined by joint damage causing effusion-synovitis that leads to worsening pathology and ultimately leads to the accelerated joint decline that is observed in AKOA.

Joint symptoms and effusion-synovitis during this early phase coincide with other structural alterations. For example, a possible sign that the joint experiences abnormal biomechanical loading early in the disease process is that degenerative cruciate ligaments [11, 15], meniscal pathology [15], and thicker medial femoral cartilage (possibly cartilage swelling) [8] are pathologic features on magnetic resonance imaging that may discriminate people who will develop AKOA over the subsequent 2 to 4 years. These pathologic findings may be caused by abnormal arthrokineamatics (e.g., laxity) or contribute to abnormal arthrokineamatics that lead to local inflammation. In the first scenario, a person may have altered arthrokineamatics leading to these pathologic findings because of acquired poor movement patterns or poor neuromuscular control secondary to a large effusion-synovitis volume [24–26]. In the second scenario, the degenerative cruciate ligaments could introduce rotational or antero-posterior knee instability and increased external adduction moments during walking, which contributes to meniscal pathology and large effusion-synovitis volumes [27]. These early risk factors or markers of AKOA may suggest we should explore the benefit of early use of arthrocentesis, anti-inflammatory therapies, or physical rehabilitation focused on neuromuscular control for people at risk for AKOA.

At 2 years prior to radiographic onset, people who developed AKOA have significantly higher odds of having meniscal pathology than controls, especially destabilizing meniscal tears (odds ratio = 4.7) [8]. Destabilizing meniscal tears compromise meniscal function and load distribution properties [28, 29] and consist of a radial tear (including a root tear) or complex tear, which almost always includes a radial component [8]. The adults who develop AKOA are also more likely to have meniscal damage in 2 or more regions (66% vs 30%), any medial meniscal pathology (excluding extrusion; 72% vs 39%), and medial meniscal extrusion (20% vs 6%), compared with adults with no knee osteoarthritis over the next 4 years [8].

These early findings highlight that adults who develop AKOA experience greater preradiographic disease burden than their peers who develop typical or no knee osteoarthritis over the next 4 years. It remains unclear why the joint is experiencing excessive disease burden during this early phase. The joint may be susceptible to these early pathologic changes because of a genetic predisposition or developmental susceptibility that leaves their tissues ill-prepared to handle joint loading, or the joint is exposed to excessive overloading with inadequate recovery that leads to increased local inflammation and aberrant tissue changes [30]. While clarifying the etiology of these early changes could yield novel prevention strategies, it is essential to also take steps to identify people without radiographic knee osteoarthritis that report greater joint symptoms and may have magnetic resonance imaging evidence of greater disease burden to help prevent accelerated disease onset and progression.

1 to 2 years before radiographic osteoarthritis onset

**Clinical**

Between 2 to 1 year before disease onset people who develop AKOA are more likely to report greater knee pain than earlier assessments [5]. Chair-stand pace and self-reported global impact of arthritis also start to worsen
among those who develop AKOA while those with typical knee osteoarthritis stay the same or improve slightly [5]. These worsening symptoms correspond to the start of a dramatic rate of changes within the joint.

**Structural alterations**

During the 2 years before radiographic disease onset, adults who develop AKOA have, on average, a 4.6 times greater increase in effusion-synovitis volume compared with their peers with typical knee osteoarthritis [16]. Additionally, they experience, on average, a 13 times greater increase in bone marrow lesion volume and a greater loss of articular cartilage than adults with typical knee osteoarthritis [8]. Unlike typical knee osteoarthritis, which may be conceptualized with focal cartilage damage, adults who develop AKOA experience diffuse cartilage changes throughout the knee [31]. Overall, these early changes characterize the start of a downward slope towards joint failure. It will be helpful to learn whether an intervention could halt or slow this progression or if they have already passed a point of no return.

**Less than 1 year before radiographic onset**

**Clinical**

Within the 12-months before disease onset, people who develop AKOA (31%) or typical knee osteoarthritis (21%) are more likely to report frequent use of medication for pain, aching, or stiffness compared with those with no knee osteoarthritis (10%) [6]. Despite the frequent use of medication to manage symptoms, people who develop AKOA or typical knee osteoarthritis during the next 12 months report greater symptoms in most activities than those without incident knee osteoarthritis. More specifically, people who develop AKOA are more likely to report greater difficulty with lying down, pain with straightening the knee, pain walking, daily knee pain, and frequent knee swelling compared with peers who will develop typical knee osteoarthritis [6].

**Structural alterations**

This peak in prodromal symptoms corresponds to continued worsening throughout the knee; including worsening bone marrow lesions, increasing effusion-synovitis volumes, and more frequent occurrence of infrapatellar fat pad signal-intensity alterations, meniscal damage in 2 or more regions, any medial meniscal pathology or extrusion, or lateral meniscal extrusion than adults with either typical or no knee osteoarthritis [8,16]. These changes may be secondary to diffuse differences in tissue composition or secondary to joint instability.

A new knee injury – especially within 1 year before radiographic onset

If a susceptible knee has large effusion-synovitis or degenerative cruciate ligaments that contribute to altered lower extremity biomechanics, then it is no surprise that these adults also report more knee injuries than their peers. Specifically, a single new injury may be a critical event that leads to joint failure or characterizes the onset of AKOA [1, 9, 32]. A history of a knee injury several years before the onset of AKOA is unrelated to disease onset [1, 9]. However, an injury in the year or two before incident knee osteoarthritis is more common among adults that develop AKOA or typical knee osteoarthritis than those who do not develop knee osteoarthritis [1]. Furthermore, a knee injury may be especially likely to lead to AKOA among normal weight and older individuals (65 years or older) or overweight-obese individuals (Fig. 1) [10]. Among people with incident AKOA, 26% were older or overweight/obese and reported a new injury in the year before developing disease onset. In contrast, only 8 and 3% of people with incident typical knee osteoarthritis or no knee osteoarthritis were older or overweight/obese and reported a new injury (Fig. 1) [10]. Hence, a new knee injury to a joint already susceptible because of other risk factors may increase the risk of an accelerated rate of joint failure.

The interaction between other risk factors and a knee injury is consistent with evidence from the destabilizing medial meniscal (DMM) mouse model. The DMM model is a surgical model that relies on destabilizing the medial meniscus to mimic human clinical meniscal injury, especially a destabilizing meniscal tear [33, 34]. The natural history of disease progression after DMM is similar to spontaneous onset [33, 35]; however, greater age [36, 37] and high-fat diets [38] are risk factors for accelerated disease onset after DMM. Furthermore, while a sex-age interaction is not reported among studies of AKOA, there is evidence that this interaction may be relevant in the DMM model. With a DMM model, orchiectomized male mice (lower testosterone) had less severe osteoarthritis than other males while ovariectomized female mice (lower sex hormones) had greater disease severity than other females. The interaction between injury, sex, sex hormones, and age may explain why simplistic analyses of sex differences in AKOA are null and, therefore, a more nuanced study may be needed [34].

We must be cautious about relying solely on self-reported injury because adults who develop AKOA may fail to perceive a traumatic event as a knee injury [32]. For example, among people who develop AKOA that failed to report an injury, almost 40% had distinct structural changes on magnetic resonance images, typically incident medial meniscal pathology [32]. Hence, it became critical to understand the key structures that
experienced trauma around the time of disease onset. Ultimately, destabilizing meniscal tears (i.e., radial tears, root tears, complex tears) and trauma to the subchondral bone characterized the trauma that led to or characterized the onset of AKOA instead of typical knee osteoarthritis [8, 32, 39, 40].

By the time people present with AKOA, they are >7 times more likely to have a destabilizing meniscal tear than those without AKOA [8]. Furthermore, over 90% of adults with AKOA have meniscal damage in 2 or more regions, 85% have medial meniscal pathology, and 77% of individuals with AKOA have meniscal extrusion [8].

It is paramount that we identify people prior to this devastating trauma and strive to prevent trauma, which is likely the tipping point from which a joint is unable to recover and ultimately leads to a quick onset of joint failure. Collectively, this evidence supports a call that if a patient is referred to physical therapy for knee pain they may benefit from establishing a goal to prevent a new joint injury that could either be the catalyst for joint failure or define a pivotal moment in the process of joint failure.

**Summary of natural history**

In summary, the natural history of incident AKOA can be conceptualized as three phases (Fig. 2). Starting at least 2 years in advance of radiographic onset, adults with AKOA may experience greater effusion-synovitis, thicker articular cartilage, diffuse meniscal pathology (including destabilizing meniscal tears), and degenerative changes in the cruciate ligaments and extensor mechanism. Hence, during this early phase, a joint is already experiencing greater preradiographic disease burden than their peers, which may explain why they report more prodromal symptoms than those who develop typical knee osteoarthritis. The subsequent 12-month phase is defined by a dramatic rate of worsening in effusion-synovitis, bone marrow lesions, and articular cartilage (Fig. 2).

Within 12 months before radiographic onset, adults with AKOA report more joint symptoms, frequent use of pain medication, frequent knee swelling, and daily knee pain compared with those who develop typical knee osteoarthritis. The greater knee pain could contribute to a new knee injury, which is often characterized by a destabilizing meniscal tear. The joint trauma may be a triggering event in a joint with an impaired ability to heal, which ultimately leads to joint failure. The compromised ability to heal in response to an injury may complement evidence from young adult rats performing a high-repetition, high-force reaching and lever pulling task [30, 41]. This model may suggest that the damage-
repair theory may be relevant to trabecular changes [42] and that damage accumulates in the bone if the loading is so high that self-repair mechanisms cannot keep pace with the level of damage or overloading-induced bone resorption. When rats perform the high-repetition, high-force task for 18 weeks, they exhibit several catabolic indices in trabeculae in their distal radial metaphyses, including decreased trabecular bone volume, increased woven bone, osteoclast numbers, microcracks and osteocyte apoptosis, compared to control rats. The loss of trabecular bone volume enhances brittleness and increases fracture risk [43]. These catabolic bone changes with high demand tasks are also consistent with the fatigue-failure theory for musculoskeletal disorder injuries [44]. Hence, overloading a knee joint beyond its capacity to repair may contribute to the accumulation of bone damage, which could explain why adults with AKOA develop larger bone marrow lesions and are more likely to develop attrition or subchondral insufficiency fractures than their peers [8, 39].

Clinical consequences of accelerated knee osteoarthritis

At an individual level, we’ve described how adults with AKOA experience greater symptoms and functional impairments starting up to 3 years prior to radiographic disease onset. This complements findings that over the first 8 years of the Osteoarthritis Initiative, people who develop AKOA are more likely to report receiving arthroscopic knee surgery, intra-articular injections (i.e., hyaluronic acid, corticosteroids), and nonsteroidal anti-inflammatory drugs (over the counter or prescription) than people who develop typical or no knee osteoarthritis [45]. Even prior to the onset of radiographic evidence of AKOA, people who will develop AKOA are more likely to use certain prescription analgesics (e.g., acetaminophen, celecoxib, aspirin) and receive arthroscopic knee surgery than those who will develop typical knee osteoarthritis [45].

The greater personal burden of AKOA is further highlighted by the high rate of knee replacements. While most people who started the Osteoarthritis Initiative without radiographic knee osteoarthritis did not receive
a knee replacement over the first 9 years of the study (≤1%), almost 1 in 7 knees with AKOA received a knee replacement during that period [7]. Furthermore, the median time from any increase in radiographic severity (change in KL grade) to knee replacement was 2.3 years (range 0.3 to 7.3 years) compared with the few knees with typical osteoarthritis that received a knee replacement (3.0 years; range 1.7 to 4.2 years) [7]. Adults with AKOA experience significant disease burden and have only a short window of opportunity to intervene, with 1 in 14 knees receiving a knee replacement in less than 2.3 years after the first evidence of radiographic progression.

Another concern is that our perception of osteoarthritis may be biased by our failure to account for people with AKOA. Within the Osteoarthritis Initiative, AKOA accounts for more than 1 in 5 cases of incident knee osteoarthritis [1]. Hence, factors that have a strong relationship with AKOA, but not typical knee osteoarthritis, may still appear associated with knee osteoarthritis overall. For example, excluding people with incident AKOA from analyses that defined incident knee osteoarthritis as at least a 2-point increase in radiographic severity led to smaller effect estimates (Cohen’s d [46]) when comparing cases of incident disease to controls: knee pain over time (d = 0.41 for everyone, d = 0.14 after excluding AKOA) or recent knee injury (OR = 5.4 for everyone, OR = 4.0 after excluding AKOA) [3]. It is essential that we critically assess our current conceptual model of knee osteoarthritis by accounting for differences among phenotypes or clinically relevant subsets (e.g., AKOA). Furthermore, we need to consider the consequences of recruiting people with AKOA into clinical trials. Separate trials may be necessary for AKOA and other types of knee osteoarthritis given AKOA has a distinct natural history defined by the onset of a destabilizing meniscal tear in a joint already susceptible to failure. A critical question is whether people with AKOA will respond differently to therapeutic interventions when compared to those with typical osteoarthritis.

Classifying adults at risk for accelerated knee osteoarthritis

To develop prevention strategies and clinical trials for adults at risk for AKOA, it is crucial to identify who will likely develop AKOA. Riddle and colleagues developed a prediction rule to estimate the chance of incident AKOA over the subsequent 5 years and found that the presence of possible knee osteoarthritis (KL = 1), contralateral knee osteoarthritis, greater BMI, and joint symptoms (total Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC] score) increased the chance of someone developing AKOA [4]. While this prediction rule provided valuable insights into identifying people at risk for AKOA, it inadequately addressed the complex interactions among the risk factors, and it lacked MR-based structural features that may help classify individuals at risk for AKOA. Hence, we used classification and regression tree (CART) analyses, which can 1) identify the most statistically important factors and the associated cut points to most efficiently differentiate groups for classifying individuals, and 2) account for complex interactions that may optimize the ability to classify individuals at risk for AKOA. Furthermore, we used the CART analyses to explore if MR-based structural findings could help classify people at high risk for AKOA (54 people developed AKOA and 108 sex-matched Osteoarthritis Initiative participants). There is consistent evidence that age, fasting glucose concentrations, and static knee alignment were statistically important clinical factors to consider when classifying people at risk for incident AKOA [11, 12]. Effusion-synovitis volume and cruciate ligament degeneration may also be statistically important for classifying people at risk for AKOA over the subsequent 4 years [11]; however, adding data from magnetic resonance imaging (e.g., quantitative effusion-synovitis, cartilage damage, bone marrow lesions; semiquantitative assessments of menisci, tendons, ligaments) failed to improve the ability to classify adults who develop AKOA over the models with only clinical measures (Table 1). Furthermore, the models failed to explain the majority of the variance that contribute to someone being classified as incident AKOA or not. Hence, we are either missing a major factor that contributes to classifying people with AKOA or there are numerous factors that contribute a little to the classification. Going forward, it will be important to better understand the earliest phases of AKOA to develop strategies to identify people at risk for or with early-stage AKOA.

**Table 1 Performance of Classification Rules for People who Will Develop AKOA Over the Subsequent 4 Years**

|                | Clinical Model | Clinical + MRI Model |
|----------------|---------------|----------------------|
| Specificity    | 0.82          | 0.90                 |
| Sensitivity    | 0.70          | 0.62                 |
| Explained Variance (%) | 41%           | 39%                  |

*Note: AKOA = accelerated knee osteoarthritis, MRI = magnetic resonance imaging*

*The final clinical classification tree included age, body mass index, serum glucose concentrations, femorotibial alignment angle, serum glycated serum protein concentrations, WOMAC knee-related function score, and coronal tibial slope angle [11]*

*The final clinical+MRI classification tree included body mass index, serum glucose concentrations, effusion-synovitis volume, presence of cruciate ligament degeneration, and coronal tibial slope angle [11]*
Accelerated knee osteoarthritis within the context of rapidly progressive osteoarthritis and destructive arthropathies

Numerous terms have been used during the last 60 years in the medical literature to describe a dramatic change in joint health; including rapidly progressive disease, rapidly destructive disease, accelerated degeneration, massive osteolysis, rapid chondrolysis, among others. The heterogeneity in nomenclature reflects uncertainty about how to classify rapidly destructive forms of osteoarthritis and their underlying mechanisms.

It is informative to reassess the existing literature and consider how various definitions may impact the reported epidemiology of rapidly progressive or accelerated osteoarthritis. For example, in Table 2, we offer several definitions of accelerated or rapidly progressive osteoarthritis and how the incidence using these definitions vary from 0 to 22% within the Osteoarthritis Initiative.

Recently, two classifications for rapidly progressive osteoarthritis have been adopted to characterize the rapid joint destruction observed in clinical trials for anti-nerve growth factor (NGF) agents [51, 52]. Rapid progressive osteoarthritis type 1 is similar to an early definition provided by Lequesne [50] that requires more than 2 mm of loss in joint space width in less than one year. Rapid progressive osteoarthritis type 2 is defined by abnormal bone loss or destruction (e.g., osteolysis) [51, 52]. Within the context of the anti-NGF clinical trials, these types of rapid progressive osteoarthritis usually (but not always) manifest in a joint in which osteoarthritis was already present [53]. In contrast, research focused on AKOA has focused on incident disease [4, 40, 54]. While these differences may be consequent on the phenomena together or extracting results from one type of osteoarthritis to another. Further studying the similarities and differences between AKOA and other forms of rapidly progressive osteoarthritis may yield new insights into these subsets of osteoarthritis.

Table 2 Frequency of Accelerated or Rapid KOA Using Previously Reported Definitions Among Adults without Radiographic KOA at OAI Baseline

| Term                                      | Radiographic Change                                      | Time Frame | Incidence in OAI |
|-------------------------------------------|----------------------------------------------------------|------------|------------------|
| Accelerated OA [1, 3, 4]                   | KL 0 or 1 to KL 3 or 4                                   | 4 or 5 years | 7.2%             |
| Rapid Radiographic Change [47]            | KL 0 or 1 then KL change ≥ 2                             | 4 or 5 years | 12.4%            |
| Fast JSW Loss [48]                        | > 0.25 mm medial JSW change                              | 1 year     | 15.5 to 22.1%    |
| Rapid Progressors [49]                    | > 1.05 mm medial JSW change                              | 1 year     | 0.4 to 0.8%      |
| Rapid Destructive Arthrosis [50]          | > 2 mm JSW change or 50% narrowing                       | 1 year     | 0%               |
| Rapid Progressive OA Type 1 [46, 47]      | > 2.00 mm JSW change                                     | 1 year     | 0%               |
| Rapid Progressive OA Type 2 [46, 47]      | abnormal bone loss or destruction                       | short period of time | 0%               |

Note: KOA knee osteoarthritis, OAI Osteoarthritis Initiative, OA osteoarthritis, JSW joint space width

Despite differences between AKOA and rapid progressive osteoarthritis, some interesting similarities may be worth exploring further. Both are more common among older adults and may be antedated by certain analgesic medications [45]. Furthermore, people who develop AKOA or rapid progressive osteoarthritis have early evidence of cartilage degradation followed by an extreme rate of articular cartilage loss [8, 31, 57] and early evidence of inflammation [11, 15, 16, 57]. Finally, 12% of knees that develop AKOA experience attrition or subchondral fractures [8] and 35% of people who develop accelerated hand osteoarthritis develop new central erosions in other hand joints [58]. While people with accelerated osteoarthritis never experience the dramatic bone destruction or collapse seen with some types of rapid progressive osteoarthritis it may be beneficial to further explore the role of bone changes in each type of osteoarthritis.

Until we reach greater clarity about the pathogeneses of these subsets of osteoarthritis, it may be inappropriate to conflate them in clinical practice or research studies. Furthermore, we need to be cautious about collapsing these phenomena together or extracting results from one type of osteoarthritis to another. Further studying the similarities and differences between AKOA and other forms of rapidly progressive osteoarthritis may yield new insights into these subsets of osteoarthritis.

Conclusions

Accelerated osteoarthritis is distinct from typical osteoarthritis. The incidence of AKOA is likely greater than example, no one with AKOA in the Osteoarthritis Initiative experienced more than 2 mm of loss in joint space width in less than one year nor abnormal bone loss or destruction. Furthermore, rapid progressive osteoarthritis is often described in knees, hips, or shoulders [46, 50, 53, 55, 56]. However, accelerated osteoarthritis is primarily observed in the knee and, to a lesser extent, the hand. Therefore, it is unclear how rapid progressive osteoarthritis at large ball-and-socket joints relates to findings at the knee.

The heterogeneity in nomenclature reflects uncertainty about how to classify rapidly destructive forms of osteoarthritis and their underlying mechanisms.
commonly perceived and could have a profound impact on epidemiologic studies and clinical trials. There is an urgent need to consider this subset of osteoarthritis when performing clinical research and to create standard nomenclature for the array of arthropathies that may be related but distinct from AKOA.

**Abbreviations**

AKOA: Accelerated knee osteoarthritis; BMI: Body mass index; DM: Distalizing medial meniscal; JSW: Joint space width; KL: Kellgren-Lawrence; KOA: Knee osteoarthritis; MRI: Magnetic resonance imaging; NGF: Nerve growth factor; OA: Osteoarthritis; OAI: Osteoarthritis Initiative; OR: Odds ratio

**Acknowledgments**

Not applicable.

**Authors’ contributions**

All authors contributed to the conception, interpretation of data, drafting/ revisions of article, provided final approval of the version to be published, and agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

**Funding**

These analyses were financially supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health under Award Number R01 AR065977. The OAI is a public-private partnership comprised of five contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the National Institutes of Health, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Private funding partners include Merck Research Laboratories; Novartis Pharmaceuticals Corporation; GlaxoSmithKline; and Pfizer, Inc. Private sector funding for the OAI is managed by the Foundation for the National Institutes of Health. This manuscript was prepared using an OAI public-use data set and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. Dr. Lo is supported by K23 AR062127, an NIH/NIAMS funded mentored award, providing support for design and conduct of the study, analysis, and interpretation of the data. This work is supported in part with resources at the VA HSR&D Center for Innovation in Quality, Effectiveness and Safety (#CIN 13–413), at the Michael E. DeBakey VA Medical Center, Houston, TX. Dr. Barbe is supported by R01 AR056919 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health, providing support for her contribution of information and interpretation of data. The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs or NIH NIAMS.

**Availability of data and materials**

The datasets analyzed during current study are available in the OAI repository, https://oai.nlm.nih.gov/oa

**Ethics approval and consent to participate**

Institutional review boards at all OAI clinical sites and coordinating center (University of California, San Francisco) approved the study. The OAI has been approved and meets all criteria for ethical standards regarding human and animal studies defined in the 1964 Declaration of Helsinki and all amendments made after. Institutional review boards at each OAI clinical site and the OAI coordinating center (University of California, San Francisco) approved the OAI study (approval number 10–00532). All participants provided informed consent prior to participation.

**Consent for publication**

Not applicable.

**Competing interests**

JBD, MFB, and MSH are members of the Editorial Board of BMC Musculoskeletal Disorders. JBD also reported payment for lectures from Pfizer, Inc. and consultancy from Pfizer/Lilly. TEM reported consultancy from Pfizer, Sanofi Aventis US, Kolon Tissuegene, Samunmed, Seikagaku, Kinik Pharma pharmaceuticals, and Anika Therapeutics. The other authors declare that they have no competing interests.

**Author details**

1 Division of Rheumatology, Allergy & Immunology, Tufts Medical Center, 800 Washington Street, Box #406, Boston, MA 02111, USA. 2 Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester, MA, USA. 3 Department of Anatomy and Cell Biology, Temple University School of Medicine, 3500 North Broad Street, Philadelphia, PA 19140, USA. 4 Department of Radiology, Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA. 5 Department of Radiology, University of Cambridge School of Clinical Medicine, Box 218, Level 5, Addenbrooke’s Hospital, Cambridge CB2 0QQ, UK. 6 Department of Radiology, Norwich Medical School, University of East Anglia, Research Park NR4 7UJ, Norwich, UK. 7 Milken Institute of Public Health, The George Washington University, 950 New Hampshire Ave NW, Washington, DC 20052, USA. 8 Brigham and Women’s Hospital and Harvard Medical School, 75 Francis Street PBB-B3, Boston, MA 02115, USA. 9 The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, 800 Washington Street, Box #63, Boston, MA 02111, USA. 10 Tufts Clinical and Translational Science Institute, Tufts University, 800 Washington Street, Box #63, Boston, MA 02111, USA. 11 Center for Primary Care and Prevention, Alpert Medical School of Brown University, 111 Brewster Street, Pawtucket, RI 02860, USA. 12 Medical Care Line and Research Care Line, Houston Health Services Research and Development (HSR&D) Center of Excellence Michael E. DeBakey VAMC, Houston, TX, USA. 13 Section of Immunology, Allergy, and Rheumatology, Baylor College of Medicine, Houston, TX. 1 Baylor Plaza, BCM-285, Houston, TX 77030, USA.

Received: 22 November 2019 Accepted: 25 May 2020

Published online: 29 May 2020

**References**

1. Driban JB, Eaton CB, Lo GH, Ward RJ, Lu B, McAlindon TE. Association of knee injuries with accelerated knee osteoarthritis progression: data from the osteoarthritis initiative. Arthritis Care Res (Hoboken). 2014;66(1):1673–9.
2. Driban JB, Bansuru RR, Eaton CB, Specter TD, Hart DJ, McAlindon TE, Lu B, Lo GH. Arden NK. The incidence and characteristics of accelerated knee osteoarthritis among women: the Chingford cohort. BMC Musculoskeletal Disord. 2020;21(1):60.
3. Driban JB, Stout AC, Lo GH, Eaton CB, Price LL, Lu B, Barbe MF, McAlindon TE. Best performing definition of accelerated knee osteoarthritis: data from the osteoarthritis initiative. Ther Adv Musculoskelet Dis. 2016;8(5):165–71.
4. Riddle DL, Stratford PW, Perera RA. The incident tibiofemoral osteoarthritis with rapid progression phenotype: development and validation of a prognostic prediction rule. Osteoarthr Cartil. 2016;24(12):2100–7.
5. Driban JB, Price LL, Eaton CB, Lu B, Lo GH, Lapane KL, McAlindon TE. Individuals with incident accelerated knee osteoarthritis have greater pain than those with common knee osteoarthritis progression: data from the osteoarthritis initiative. Clin Rheumatol. 2016;35(6):1565–71.
6. Davis J, Eaton CB, Lo GH, Lu B, Price LL, McAlindon TE, Barbe MF, Driban JB. Knee symptoms among adults at risk for accelerated knee osteoarthritis: data from the osteoarthritis initiative. Clin Rheumatol. 2017;36(5):1083–9.
7. Davis JE, Liu SH, Lapane K, Harkey MS, Price LL, Lu B, Lo GH, Eaton CB, Barbe MF, McAlindon TE; et al. Adults with incident accelerated knee osteoarthritis are more likely to receive a knee replacement: data from the osteoarthritis initiative. Clin Rheumatol. 2018;37(4):1115–8.
8. Driban JB, Davis JE, Lu B, Price LL, Ward RJ, Mackay JW, Eaton CB, Lo GH, Barbe MF, Zhang M, et al. Accelerated knee osteoarthritis is characterized by destabilizing meniscal tears and Preradiographic structural disease burden. Arthritis Rheumatol. 2019;71(7):1089–100.
9. Davis JE, Price LL, Eaton CB, McAlindon TE, Lu B, Barbe MF, Driban JB. A single recent injury is a potent risk factor for the development of accelerated knee osteoarthritis: data from the osteoarthritis initiative. Rheumatol Int. 2017;37(10):1759–64.
10. Driban JB, Eaton CB, Lo GH, Price LL, Lu B, Barbe MF, McAlindon TE. Overweight older adults, particularly after an injury, are at high risk for accelerated knee osteoarthritis: data from the osteoarthritis initiative. Clin Rheumatol. 2016;35(4):1071–6.
11. Price LL, Harkey MS, Ward RJ, Mackay JW, Zhang M, Pang J, Davis JE, McAlindon TE, Lo GH, Amin M, et al. Role of magnetic resonance imaging in classifying individuals who will develop accelerated radiographic knee osteoarthritis. J Orthop Res. 2019;37(11):2420–8.

12. Driban JB, McAlindon TE, Amin M, Price LL, Eaton CB, Davis JE, Lu B, Lo GH, Duryea J, Barbe MF. Risk factors can classify individuals who develop accelerated knee osteoarthritis: data from the osteoarthritis initiative. J Orthop Res. 2018;36(3):876–80.

13. Driban JB, Eaton CB, Amin M, Stout AC, Price LL, Lu B, Lo GH, McAlindon TE, Barbe MF. Glucose homeostasis influences the risk of incident knee osteoarthritis: data from the osteoarthritis initiative. BMC Musculoskel Disord. 2016;17:299.

14. Harkey MS, Davis JE, Lu B, Price LL, Ward RJ, Mackay JW, Eaton CB, Lo GH, Barbe MF, Zhang M, et al. Early pre-radiographic structural pathology precedes the onset of accelerated knee osteoarthritis. BMC Musculoskel Disord. 2019;20(1):241.

15. Davis JE, Ward RJ, Mackay JW, Lu B, Price LL, McAlindon TE, Eaton CB, Barbe MF, Lo GH, Harkey MS, et al. Effusion-synovitis and infrapatellar fat pad signal intensity alteration differentiate accelerated knee osteoarthritis. Rheumatol (Oxford). 2019;58(3):418–26.

16. Stout AC, Barbe MF, Eaton CB, Amin M, Ai-Eid F, Price LL, Lu B, Lo GH, Zhang M, Pang J, et al. Inflammation and glucose homeostasis are associated with specific structural features among adults without knee osteoarthritis: a cross-sectional study from the osteoarthritis initiative. BMC Musculoskel Disord. 2018;19(1):1.

17. Wang X, Jin X, Han W, Cao Y, Halliday A, Blizzard L, Pan F, Antony B, Cicuttini F, Jones G, et al. Cross-sectional and longitudinal associations between knee joint effusion Synovitis and knee pain in older adults. J Rheumatol. 2016;43(1):121–30.

18. Jaivaid MK, Kitan A, Guermazi A, Kwoh CK, Zaim S, Carbone L, Harris T, Mcculloch CE, Arden NK, Lane NE, et al. Individual magnetic resonance imaging and radiographic features of knee osteoarthritis in subjects with unilateral knee pain: the health, aging, and body composition study. Arthritis Rheum. 2012;65(10):3246–55.

19. Hunter DJ, Zhang W, Conaghan PG, Hirko K, Menashe L, Li L, Reichmann WM, Losina E. Systematic review of the concurrent and predictive validity of MRI biomarkers in OA. Osteoarthr Cartil. 2011;19(5):575–87.

20. Yusuf E, Kontekeas MC, Watt I, Huizinga TW, Kloppenburg M. Do knee abnormalities visualised on MRI explain knee pain in knee osteoarthritis? A systematic review. Ann Rheum Dis. 2011;70(10):1860–7.

21. Wang X, Jin X, Blizzard L, Antony B, Han W, Zhu Z, Cicuttini F, Wuka AE, Wiroenbergh T, Tung G, et al. Associations between knee-synovitis and joint structural changes in patients with knee osteoarthritis. J Rheumatol. 2017;44(11):1644–51.

22. Roemer FW, Guermazi A, Felson DT, Niu J, Nevitt MC, Crema MD, Lynch JA, Lewis CE, Tonner J, Zhang Y. Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 792-month follow-up: the MOST study. Ann Rheum Dis. 2011;70(10):1860–9.

23. Palmeri RM, Wehmian A, Edwards JE, Tom J, Saliba EN, Mistry DJ, Ingersoll CD. Pre-synaptic modulation of quadriceps arthrogenic muscle inhibition. Knee Surg Sports TraumatolArthrosc. 2005;13(5):570–6.

24. Palmeri RM, Tom J, Edwards JE, Wehmian A, Saliba EN, Mistry DJ, Ingersoll CD. Arthrogenic muscle response induced by an experimental knee joint effusion is mediated by pre- and post-synaptic spinal mechanisms. J ElectromyogrKinesiol. 2004;14(6):631–40.

25. Palmeri RM, Ingersoll CD, Edwards JE, Hoffman MA, Stone MB, Babington JP, Cordova ML, Krause BA. Arthrogenic muscle inhibition is not present in the limb contralateral to a simulated knee joint effusion. Am J Phys Med Rehabil. 2003;82(12):910–6.

26. Hovis KK, Aliza H, Tham S-C, Souza RB, Nevitt MC, McCulloch CE, Link TM. Non-traumatic anterior cruciate ligament abnormalities and their relationship to osteoarthritis using morphological grading and cartilage T2 relaxation times: data from the osteoarthritis initiative (OAI). Skelet Radiol. 2012;41(11):1435–43.

27. Guermazi A, Hayashi D, Jaraya M, Roemer FW, Zhang Y, Niu J, Crema MD, Englund M, Lynch JA, Nevitt MC, et al. Medial posterior meniscal root tears are associated with development or worsening of medial tibiofemoral cartilage damage: the multicenter osteoarthritis study. Radiology. 2013;268(3):814–21.

28. Kych AJ, Reardon PJ, Johnson NR, Mohan R, Peter L, Levy BA, Stuart MJ. Non-operative management of medial meniscus posterior horn root tears is associated with worsening arthritis and poor clinical outcome at 5-year follow-up. Knee Surg Sports Traumatol Arthrosc. 2017;25(2):383–9.

29. Driban JB, Barr AE, Amin M, Stier MR, Barbe MF. Joint inflammation and early degeneration induced by high force reaching are attenuated by ibuprofen in an animal model of work-related musculoskeletal disorder. J Biomed Biotechnol. 2011;2011:691412.

30. Harkey MS, Davis JE, Lu B, Price LL, Eaton CB, Lo GH, Barbe MF, Ward RJ, Zhang M, Liu SH, et al. Diffuse tibiofemoral cartilage change prior to the development of accelerated knee osteoarthritis: data from the osteoarthritis initiative. Clin Anat. 2019;32(3):369–78.

31. Davis JE, Harkey MS, Ward RJ, Mackay JW, Lu B, Price LL, Eaton CB, Barbe MF, Lo GH, McAlindon TE, et al. Characterizing the distinct structural changes associated with self-reported knee injury among individuals with incident knee osteoarthritis: data from the osteoarthritis initiative. Clin Anat. 2018;31(3):330–4.

32. Glasson SS, Blanchet TJ, Morris EA. The surgical destabilization of the medial meniscus (DDM) model of osteoarthritis in the 129/SvEv mouse. Osteoarthr Cartil. 2007;15(9):1061–9.

33. Ma HL, Blanchet TJ, Peluso D, Hopkins B, Morris EA, Glasson SS. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthr Cartil. 2007;15(6):695–700.

34. McNulty MA, Looser RF, Davey C, Callahan MF, Ferguson CM, Carlson CS. Histopathology of naturally occurring and surgically induced osteoarthritis in mice. Osteoarthr Cartil. 2012;20(8):949–56.

35. Meckes JK, Carames B, Olmer M, Kosses WP, Grogan SP, Lotz MK, D’Lima DD. Compromised autophagy precedes meniscus degeneration and cartilage damage in mice. Osteoarthr Cartil. 2017;25(11):1880–9.

36. Huang H, Skelly JD, Ayers DC, Song J. Age-dependent changes in the articular cartilage and Subchondral bone of C57BL/6 mice after surgical destabilization of medial meniscus. Sci Rep. 2017;7:42294.

37. Datta P, Zhang Y, Parousis A, Sharma A, Rossmoacha E, Endhisa H, Wu B, Kapczik I, Mahomed NN, Gandhi R, et al. High-fat diet-induced acceleration of osteoarthritis is associated with a distinct and sustained plasma metabolite signature. Sci Rep. 2017;7(1):8205.

38. Driban JB, Ward RJ, Eaton CB, Lo GH, Price LL, Lu B, McAlindon TE. Meniscal extrusion or subchondral damage characterize incident accelerated osteoarthritis: data from the osteoarthritis initiative. Clin Anat. 2015;28(6):792–9.

39. Foreman SC, Neumann J, Joseph GB, Nevitt MC, McCulloch CE, Lane NE, Link TM. Longitudinal MRI structural findings observed in accelerated knee osteoarthritis: data from the osteoarthritis initiative. Skelet Radiol. 2019.

40. Jain G, Barr-Gillespie AE, Clark BD, Kethys DM, Wade CK, Litvin J, Popoff SN, Barbe MF. Bone loss from high repetitive high force loading is prevented by ibuprofen treatment. J Musculoskel Neuronal Interact. 2014;14(1):78–94.

41. Li H, Li J, Zou Z, Fok AS. Fracture simulation of restored teeth using a continuum damage mechanics failure model. Dent Mater. 2011;27(7):125–33.

42. Tumer CH. Biomechanics of bone: determinants of skeletal fragility and bone quality. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2002;13(2):97–104.

43. Gallagher S, Schall MC Jr. Musculoskeletal disorders as a fatigue failure process: evidence, implications and research needs. Ergonomics. 2017;60(2):255–69.

44. Roemer FW, Hayes CW, Miller CG, Hoover K, Guermazi A. Imaging atlas for eligibility and on-study safety of potential shoulder adverse events in anti-NGF studies (part 3). Osteoarthr Cartil. 2015;23(4Supp1):S159–68.

45. Wesseling J, Bierma-Zeinstra SM, Kloppenburg M, Meijer R, Bijlma JW. Worsening of pain and function over 5 years in individuals with ‘early’ OA is related to structural damage: data from the osteoarthritis initiative and CHECK (Cohort hip & Cohort Knee) study. Ann Rheum Dis. 2015;74(2):347–53.
48. Neogi T, Niu J, Duryea J, Lynch J, Zhang Y: Identifying trajectories of medial joint-space width loss and associated risk factors. Osteoarthritis Cartilage 2012, 20, Supplement 1(0):S182-S183.

49. Bartlett SJ, Ling SM, Mayo NE, Scott SC, Bingham CO, 3rd: Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis. Arthritis Care Res (Hoboken) 2011, 63(12):1722–1728.

50. Lequesne M. Les coxopathies rapidement destructrices inattendues. La Presse Med. 1970;78.

51. Hochberg MC. Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthr Cartil. 2015;23(Suppl 1):S18–21.

52. Roemer FW, Hayes CW, Miller CG, Hoover K, Guermazi A. Imaging atlas for eligibility and on-study safety of potential knee adverse events in anti-NGF studies (part 1). Osteoarthr Cartil. 2015;23(Suppl 1):S22–42.

53. Hochberg MC, Tive LA, Abramson SB, Vignon E, Verburg KM, West CR, Smith MD, Hungerford DS: When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program. Arthritis & rheumatology (Hoboken, NJ) 2016, 68(2):382–391.

54. Driban JB, Eaton CB, Lo GH, Barbe MF, Ward RJ, Lu B, McAlindon TE: Knee injuries are associated with the onset of rapid knee osteoarthritis: Data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2014, 22(Supplement 1): S32-S33.

55. Flemming DJ, Gustas-French CN. Rapidly progressive osteoarthritis: a review of the clinical and radiologic presentation. Curr Rheumatol Rep. 2017;19(7):42.

56. Roemer FW, Hayes CW, Miller CG, Hoover K, Guermazi A. Imaging atlas for eligibility and on-study safety of potential hip adverse events in anti-NGF studies (part 2). Osteoarthr Cartil. 2015;23(Suppl 1):S43–58.

57. Kansal MA, Verburg KM, West CR, Bay-Jensen AC, Keller DS, Arends R. Serological biomarker profiles of rapidly progressive osteoarthritis in tanezumab-treated patients. Osteoarthr Cartil. 2019;27(3):484–92.

58. Davis JE, Schaefer LF, McAlindon TE, Eaton CB, Roberts MB, Haugen IK, Smith SE, Duryea J, Lu B, Driban JB. Characteristics of accelerated hand osteoarthritis: data from the osteoarthritis initiative. J Rheumatol. 2019;46(4):422–8.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.